Bibliographies thématiques / IMMUNOPHARMACOLOGICAL

Littérature scientifique sur le sujet « IMMUNOPHARMACOLOGICAL »

Auteur : Grafiati
Publié le 18 mai 2024

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « IMMUNOPHARMACOLOGICAL ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "IMMUNOPHARMACOLOGICAL"

1

Ielpo, M. T. L., A. Basile, R. Miranda, V. Moscatiello, C. Nappo, S. Sorbo, E. Laghi, M. M. Ricciardi, L. Ricciardi et M. L. Vuotto. « Immunopharmacological properties of flavonoids ». Fitoterapia 71 (août 2000) : S101—S109. http://dx.doi.org/10.1016/s0367-326x(00)00184-2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Kovalenko, L. P., E. V. Shipaeva, S. V. Alekseeva, A. V. Pronin, A. D. Durnev, T. A. Gudasheva, R. U. Ostrovskaja et S. B. Seredenin. « Immunopharmacological properties of noopept ». Bulletin of Experimental Biology and Medicine 144, no 1 (juillet 2007) : 49–52. http://dx.doi.org/10.1007/s10517-007-0251-3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Zhang, Jianmei, Stephanie Triseptya Hunto, Yoonyong Yang, Jongsung Lee et Jae Youl Cho. « Tabebuia impetiginosa : A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties ». Molecules 25, no 18 (18 septembre 2020) : 4294. http://dx.doi.org/10.3390/molecules25184294.

Texte intégral
Résumé :
Tabebuia impetiginosa, a plant native to the Amazon rainforest and other parts of Latin America, is traditionally used for treating fever, malaria, bacterial and fungal infections, and skin diseases. Additionally, several categories of phytochemicals and extracts isolated from T. impetiginosa have been studied via various models and displayed pharmacological activities. This review aims to uncover and summarize the research concerning T. impetiginosa, particularly its traditional uses, phytochemistry, and immunopharmacological activity, as well as to provide guidance for future research. A comprehensive search of the published literature was conducted to locate original publications pertaining to T. impetiginosa up to June 2020. The main inquiry used the following keywords in various combinations in titles and abstracts: T. impetiginosa, Taheebo, traditional uses, phytochemistry, immunopharmacological, anti-inflammatory activity. Immunopharmacological activity described in this paper includes its anti-inflammatory, anti-allergic, anti-autoimmune, and anti-cancer properties. Particularly, T. impetiginosa has a strong effect on anti-inflammatory activity. This paper also describes the target pathway underlying how T. impetiginosa inhibits the inflammatory response. The need for further investigation to identify other pharmacological activities as well as the exact target proteins of T. impetiginosa was also highlighted. T. impetiginosa may provide a new strategy for prevention and treatment of many immunological disorders that foster extensive research to identify potential anti-inflammatory and immunomodulatory compounds and fractions as well as to explore the underlying mechanisms of this herb. Further scientific evidence is required for clinical trials on its immunopharmacological effects and safety.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Kawakita, Takuya. « Immunopharmacological effects of Kampo medicines ». Folia Pharmacologica Japonica 132, no 5 (2008) : 276–79. http://dx.doi.org/10.1254/fpj.132.276.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Borriello, Francesco, Francescopaolo Granata, Gilda Varricchi, Arturo Genovese, Massimo Triggiani et Gianni Marone. « Immunopharmacological modulation of mast cells ». Current Opinion in Pharmacology 17 (août 2014) : 45–57. http://dx.doi.org/10.1016/j.coph.2014.07.002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Simbirtsev, A. S. « Immunopharmacological aspects of the cytokine system ». Bulletin of Siberian Medicine 18, no 1 (16 mai 2019) : 84–95. http://dx.doi.org/10.20538/1682-0363-2019-1-84-95.

Texte intégral
Résumé :
Cytokines represent a unique family of endogenous polypeptide mediators of intercellular interaction. From an immunopharmacological point of view cytokines can be marked out as a new, separate immunoregulatory molecule system and have some common biochemical properties and pleiotropic type of biological activity. In the cytokine regulatory system both reduction and elevation of cytokine levels can cause pathology. Several endogenous systems exist to control cytokine elevation and prevent tissue pathology. When synthesized simultaneously, cytokines form a cytokine chain. Deletion of any unit of this chain leads to the break in the formation of immunopathology. Cytokines as therapeutic preparations have evident advantages but also some limitations such as pharmacokinetics with short circulation period, adverse effects due to pleiotropic mode of action, and injectable drug forms. Rational design for clinical cytokine application could be linked with the development of prolonged and local drug forms or personalized cytokine therapy.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Farjam, Mojtaba, Guang-Xian Zhang, Bogoljub Ciric et Abdolmohamad Rostami. « Emerging immunopharmacological targets in multiple sclerosis ». Journal of the Neurological Sciences 358, no 1-2 (novembre 2015) : 22–30. http://dx.doi.org/10.1016/j.jns.2015.09.346.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Kouttab, N., M. Prada et B. Brunetti. « Immunopharmacological profile of two synthetic tripeptides ». International Journal of Immunopharmacology 10 (janvier 1988) : 126. http://dx.doi.org/10.1016/0192-0561(88)90472-9.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

IVANOVSKA, NINA, STEFAN PHILIPOV et PEPA GEORGIEVA. « IMMUNOPHARMACOLOGICAL ACTIVITY OF APORPHINOID ALKALOID OXOGLAUCINE ». Pharmacological Research 35, no 4 (avril 1997) : 267–72. http://dx.doi.org/10.1006/phrs.1996.9994.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Kirchhof, Julia, Liubov Petrakova, Alexandra Brinkhoff, Sven Benson, Justine Schmidt, Maike Unteroberdörster, Benjamin Wilde, Ted J. Kaptchuk, Oliver Witzke et Manfred Schedlowski. « Learned immunosuppressive placebo responses in renal transplant patients ». Proceedings of the National Academy of Sciences 115, no 16 (2 avril 2018) : 4223–27. http://dx.doi.org/10.1073/pnas.1720548115.

Texte intégral
Résumé :
Patients after organ transplantation or with chronic, inflammatory autoimmune diseases require lifelong treatment with immunosuppressive drugs, which have toxic adverse effects. Recent insight into the neurobiology of placebo responses shows that associative conditioning procedures can be employed as placebo-induced dose reduction strategies in an immunopharmacological regimen. However, it is unclear whether learned immune responses can be produced in patient populations already receiving an immunosuppressive regimen. Thus, 30 renal transplant patients underwent a taste-immune conditioning paradigm, in which immunosuppressive drugs (unconditioned stimulus) were paired with a gustatory stimulus [conditioned stimulus (CS)] during the learning phase. During evocation phase, after patients were reexposed to the CS, T cell proliferative capacity was significantly reduced in comparison with the baseline kinetics of T cell functions under routine drug intake (ƞp2 = 0.34). These data demonstrate, proof-of-concept, that learned immunosuppressive placebo responses can be used as a supportive, placebo-based, dose-reduction strategy to improve treatment efficacy in an ongoing immunopharmacological regimen.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "IMMUNOPHARMACOLOGICAL"

1

Roy, Subhrajyoti. « Immunopharmacological Investigation of an Edible Fern, Diplazium esculentum (Koenig ex Retz) sw.., Available in North Bengal Region ». Thesis, University of North Bengal, 2016. http://hdl.handle.net/123456789/2480.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Okayama, Yoshimichi. « Immunopharmacological studies on human mast cells and basophils ». Thesis, University of Southampton, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296403.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Govindappa, Karthik. « Immunopharmacological consequences of immune responses to therapeutic interferon beta ». Thesis, University of Liverpool, 2013. http://livrepository.liverpool.ac.uk/15173/.

Texte intégral
Résumé :
Protein therapeutics or biologics represent 30 % of current licensed pharmaceutical products. In general, biologics offer superior safety profiles compared to small molecules. However, significant clinical concerns have emerged in terms of development of anti-drug antibodies (ADAs), a phenomenon that is covered under the term, immunogenicity. Anti-drug antibodies can alter pharmacokinetics, reduce efficacy of the therapeutic and also can in some cases induce allergic reactions. Human recombinant interferon beta (IFN-β) is a biologic used for the treatment of multiple sclerosis (MS) – a chronic, inflammatory and demyelinating disease of the central nervous system. Long-term treatment with IFN-β has been shown to lead to the development of anti-IFN-β antibodies that can cause total loss or reduced efficacy. Anti-drug antibodies can be non-neutralising (N-NAb) and neutralising (NAb) depending on the site to which they bind. This study aimed to conduct a systematic review to determine factors affecting the formation of neutralising antibodies against three different formulations of IFN-β Avonex™, Rebif™ and Betaseron/Betaferon™. Findings from the systematic review highlight the relative differences in immunogenicity risk of different IFN-β formulations Avonex™, Rebif ™ and Betaseron/Betaferon™ with Avonex™ having the lowest risk, Rebif™ has moderate risk and Betaseron/Betaferon™ has high risk. Characterising the immunoglobulin profile of the IFN-β ADAs from the plasma of ADA positive MS patients revealed that IFN-β ADAs are predominantly of the IgG1 and IgG4 subclass. We also characterised the neutralising potential of the major ADA IgG4 subclass using a IFN-β bioactivity assay and show that IgG4 antibodies may likely contribute to the neutralisation activity. The potential of the neutralising ADAs to cross-react with endogenous IFN-β was investigated using an in vitro bioactivity assay. Findings from this set of experiments revealed varying degrees of neutralisation of endogenous IFN-β. We next explored the potential immunological consequence of ADA with regards to formation of immune complexes and activation of complement. The interaction of ADAs with the biologic can result in formation of immune complex. Immune complexes can activate the complement system. The data revealed IFN-β ADAs can form immune complexes with IFN-β and therefore activate complement. We also attempted to identify IFN-β linear epitopes that the ADAs had the ability to bind. However, a combination of multipin peptide technology and in vitro peptide competitive binding assay failed to reveal a definitive linear epitope although there was some evidence for the existence of potential linear epitopes. We also examined the involvement of T helper cells and T regulatory cells (Tregs) in ADA development. The data revealed no significant differences in the frequency of Tregs among IFN-β ADAs positive, negative and healthy donors. Attempts were also made to identify T helper epitopes within IFN-β that could potentially drive immunogenicity. Using T-cell epitope prediction tools (IEDB-AR and ProPred) and T-cell functional assays we identified an immunogenic sequence of 36 amino acids within IFN-β (position 130-166). Our data revealed that one IFN-β peptide within this sequence is a potential T-cell immunogenic epitope. In addition we identified a possible association of one IFN-β derived peptide with the DRB1*1501HLA haplotype. In summary, the results presented in this thesis have provided essential information on subclass profile of IFN-β ADAs, the possible involvement of T helper cells and potential antibody epitopes within IFN-β. Future studies should be aimed at providing greater detail on the evolution of the ADA response and test strategies to remove immunogenic determinants from IFN-β.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Dey, Priyankar. « Immunopharmacological investigations of the herb nerium indicum miller (apocynaceae) ». Thesis, University of North Bengal, 2015. http://hdl.handle.net/123456789/1861.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Boylan, M. T. « Immunopharmacological aspects of methylprednisolone and interferon-beta therapies in multiple sclerosis ». Thesis, Queen's University Belfast, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269028.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Dutta, Somit. « Immunopharmacological evaluation of leaf extract of an ethnomedicinal herb, croton bonplandianus baill (euphorbiaceae) ». Thesis, University of North Bengal, 2018. http://hdl.handle.net/123456789/2658.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "IMMUNOPHARMACOLOGICAL"

1

Drews, Jürgen. « Antibodies as Immunopharmacological Agents ». Dans Immunopharmacology, 92–128. Berlin, Heidelberg : Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-75561-3_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Archer, Clive B. « Immunopharmacological Mechanisms in Atopic Dermatitis ». Dans Harper's Textbook of Pediatric Dermatology, 25.1–25.13. Oxford, UK : Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444345384.ch25.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Gilman, Steven C., et Alan J. Lewis. « Immunopharmacological Approaches to Drug Development ». Dans Drug Discovery and Development, 227–56. Totowa, NJ : Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4828-6_9.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Mašek, K. « Immunopharmacological Aspects of Mental Disorders ». Dans New Concepts in Depression, 306–19. London : Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09506-3_28.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Østensen, Monika. « Immunopharmacological Treatment during Pregnancy and Lactation ». Dans Immunopharmacology in Autoimmune Diseases and Transplantation, 245–60. Boston, MA : Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-1167-4_19.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Zídek, Z., K. Mašek, M. Svobodová, K. Šůla, K. Nouza et J. Müller. « Some Immunopharmacological Properties of Adamantylamide Dipeptide (AdDP) ». Dans Immunotherapeutic Prospects of Infectious Diseases, 363–66. Berlin, Heidelberg : Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76120-1_48.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Lien, Eric J., Arima Das et Linda L. Lien. « Immunopharmacological and biochemical bases of Chinese herbal medicine ». Dans Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques, 263–80. Basel : Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-8996-4_7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Singh, Vijendra K., et H. Hugh Fudenberg. « Immunopharmacological approach to the study of chronic brain disorders ». Dans Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques, 345–63. Basel : Birkhäuser Basel, 1986. http://dx.doi.org/10.1007/978-3-0348-9311-4_10.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Chakraborty, Pritha, Moytrey Chatterjee, Ankita Chakraborty, Somrita Padma et Suprabhat Mukherjee. « Phytochemicals as Modulators of Toll-Like Receptors : An Immunopharmacological Perspective ». Dans Medicinal Plants and Antimicrobial Therapies, 49–83. Singapore : Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-7261-6_3.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Ladel, C. H., H. Püschner et U. Bamberger. « The SCID Mouse and its use for Immunopharmacological and Immunotoxicological Investigations ». Dans Archives of Toxicology, 472–87. Berlin, Heidelberg : Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79451-3_41.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « IMMUNOPHARMACOLOGICAL » pour d’autres types de sources :
Articles de revues
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie